Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

Achillion shareholders approve Alexion takeover

Shareholders of Achillion Pharmaceuticals have overwhelmingly approved the company’s takeover by fellow New Haven-born drug maker Alexion Pharmaceuticals for $930 million. Achillion said approximately 99...

| By Kelley Gipson

UConn listed among top entrepreneur programs

Almost every course in the UConn entrepreneurship curriculum has moved away from exam-based assessment and theoretical course content, in favor of building and doing. Furthermore,...

| By Kelley Gipson

JAX editing genome for cardiovascular diseases

Human somatic cell genome editing  is a promising treatment option for cardiovascular disorders, but concerns remain about the safety and efficacy of this therapeutic strategy....

| By Kelley Gipson

Biohaven reports migraine treatment effective

Biohaven Pharmaceutical Holding Company Ltd said on Tuesday two doses of its experimental treatment for acute migraine were effective in reducing headaches in a pivotal...

| By Kelley Gipson

UConn recruiting research, entrepreneurship faculty

UConn President Thomas Katsouleas set an ambitious goal last February to double research funding at the state’s flagship university over the next decade. A key part...

| By Kelley Gipson

Achillion reports data from dosing trial

Achillion Pharmaceuticals has reported top-line data from a dose-finding Phase 2 trial assessing the safety and effectiveness of its oral small molecule factor D inhibitor...

| By Kelley Gipson

UConn/JAX professor to study repeated DNA

About 50% of human DNA today is made of duplicated sequences that are the remnants of transposition events that took place in our evolutionary history....

| By Kelley Gipson

Yale scientists capture dynamic brain activity

Scientists routinely capture images of the brain in action by focusing on single molecules, cells, or circuits. But visualizing how these tiny units interact to...

| By Kelley Gipson

Cybrexa expands anticancer pipeline

Cybrexa Therapeutics reports it is expanding the application of its proprietary alphalex™ platform to include toxin conjugates and additional next generation synthetic lethality targets. Two...

| By Kelley Gipson

UConn advances Prader-Willi research

A group of researchers from the UConn School of Medicine have received a nearly $3 million grant from the National Institutes of Health to investigate...